Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.

MLA

Hagiwara, Akifumi, et al. “Diffusion MRI Is an Early Biomarker of Overall Survival Benefit in IDH Wild-Type Recurrent Glioblastoma Treated with Immune Checkpoint Inhibitors.” Neuro-Oncology, vol. 24, no. 6, June 2022, pp. 1020–28. EBSCOhost, https://doi.org/10.1093/neuonc/noab276.

APA

Hagiwara, A., Oughourlian, T. C., Cho, N. S., Schlossman, J., Wang, C., Yao, J., Raymond, C., Everson, R., Patel, K., Mareninov, S., Rodriguez, F. J., Salamon, N., Pope, W. B., Nghiemphu, P. L., Liau, L. M., Prins, R. M., Cloughesy, T. F., & Ellingson, B. M. (2022). Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-Oncology, 24(6), 1020–1028. https://doi.org/10.1093/neuonc/noab276

Chicago

Hagiwara, Akifumi, Talia C Oughourlian, Nicholas S Cho, Jacob Schlossman, Chencai Wang, Jingwen Yao, Catalina Raymond, et al. 2022. “Diffusion MRI Is an Early Biomarker of Overall Survival Benefit in IDH Wild-Type Recurrent Glioblastoma Treated with Immune Checkpoint Inhibitors.” Neuro-Oncology 24 (6): 1020–28. doi:10.1093/neuonc/noab276.